Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study

Heart Rhythm

Volumn 14, Issue 7, 2017, Pages 955-961

  Nasir, Javed M ^a,b   Pomeroy, William ^b   Marler, Adam ^b   Hann, Matthew ^b   Baykaner, Tina ^a   Jones, Ronald ^a,b   Stoll, Richard ^b   Hursey, Katherine ^b   Meadows, Angela ^b   Walker, Jennifer ^b   Kindsvater, Steve ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b USAF Medical Center Keesler   (United States)

^c Heart Hospital Baylor   (United States)

Author keywords

Atrial fibrillation; Atrial flutter; Device detected atrial fibrillation; Insertable cardiac monitor; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ABLATION THERAPY; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE INFECTION; DEVICE REMOVAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FLUTTER; HEART RATE; HUMAN; IMPLANTABLE CARDIAC MONITOR; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MEDICAL RECORD REVIEW; PACEMAKER IMPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPLICATION; DEVICES; ELECTRODE IMPLANT; EPIDEMIOLOGY; MASS SCREENING; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; PROPENSITY SCORE; RISK ASSESSMENT; THROMBOEMBOLISM; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRODES, IMPLANTED; FEMALE; HUMANS; MALE; MASS SCREENING; MONITORING, PHYSIOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOEMBOLISM; UNITED STATES;

EID: 85020914554     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2017.04.026     Document Type: Article

References (34)

1. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e39.
2. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S., D'Agostino, R.B., Massaro, J.M., Beiser, A., Wolf, P.A., Benjamin, E.J., Lifetime risk for development of atrial fibrillation. Circulation 110 (2004), 1042–1046.
3. Marini, C., De Santis, F., Sacco, S., Russo, T., Olivieri, L., Totaro, R., Carolei, A., Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36 (2005), 1115–1119.
4. Sanna, T., Diener, H.-C., Passman, R.S., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 (2014), 2478–2486.
5. Leyden, J.M., Kleinig, T.J., Newbury, J., Castle, S., Cranefield, J., Anderson, C.S., Crotty, M., Whitford, D., Jannes, J., Lee, A., Greenhill, J., Adelaide stroke incidence study. Stroke 44 (2013), 1226–1231.
6. Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
7. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
8. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
9. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
10. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
11. Kernan, W.N., Ovbiagele, B., Black, H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 45 (2014), 2160–2236.
12. Svennberg, E., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman, V., Rosenqvist, M., Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 131 (2015), 2176–2184.
13. Engdahl, J., Andersson, L., Mirskaya, M., Rosenqvist, M., Stepwise screening of atrial fibrillation in a 75-year-old population. Circulation 127 (2013), 930–937.
14. Schnabel, R.B., Sullivan, L.M., Levy, D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009), 739–745.
15. Chamberlain, A.M., Agarwal, S.K., Folsom, A.R., Soliman, E.Z., Chambless, L.E., Crow, R., Ambrose, M., Alonso, A., A clinical risk score for atrial fibrillation in a biracial prospective cohort. Am J Cardiol 107 (2011), 85–91.
16. Chyou, J.Y., Hunter, T.D., Mollenkopf, S.A., Turakhia, M.P., Reynolds, M.R., Individual and combined risk factors for incident atrial fibrillation and incident stroke: an analysis of 3 million at-risk US patients. J Am Heart Assoc, 4, 2015, e001723.
17. Brunner, K.J., Bunch, T.J., Mullin, C.M., May, H.T., Bair, T.L., Elliot, D.W., Anderson, J.L., Mahapatra, S., Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. Mayo Clin Proc 89 (2014), 1498–1505.
18. 2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study. Am J Med 129 (2016), 843–849.
19. Chao, T.-F., Liu, C.-J., Chen, S.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Tuan, T.-C., Wu, T.-J., Chen, T.-J., Chen, S.-A., CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 168 (2013), 1360–1363.
20. Hindricks, G., Pokushalov, E., Urban, L., et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 3 (2010), 141–147.
21. Lip, G.Y.H., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J.G.M., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137 (2010), 263–272.
22. Lowres, N., Neubeck, L., Redfern, J., Freedman, S.B., Screening to identify unknown atrial fibrillation: a systematic review. Thromb Haemost 110 (2013), 213–222.
23. Healey, J.S., Connolly, S.J., Gold, M.R., et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366 (2012), 120–129.
24. Reiffel JA. REVEAL AF: incidence of AF in high risk patients. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01727297. Cited October 21, 2016. Accessed January 3, 2017.
25. Healey JS, Alings M, Leong-Sit P, DeGraff J, Birnie D, Freericks M, Ha A, Verma A. Prevalence of sub-clinical atrial fibrillation using an implantable cardiac monitor in patients with cardiovascular risk factors: ASSERT II. Abstract presented at: American Heart Association's Scientific Sessions 2016; November 15, 2016; New Orleans, LA.
26. Lowres, N., Neubeck, L., Salkeld, G., et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost 111 (2014), 1167–1176.
27. Cullen, M.W., Kim, S., Piccini, J.P., et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 6 (2013), 461–469.
28. Glotzer, T.V., Daoud, E.G., Wyse, D.G., Singer, D.E., Ezekowitz, M.D., Hilker, C., Miller, C., Qi, D., Ziegler, P.D., The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2 (2009), 474–480.
29. Boriani, G., Glotzer, T.V., Santini, M., West, T.M., De Melis, M., Sepsi, M., Gasparini, M., Lewalter, T., Camm, J.A., Singer, D.E., Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project. Eur Heart J 35 (2014), 508–516.
30. Shanmugam, N., Boerdlein, A., Proff, J., Ong, P., Valencia, O., Maier, S.K.G., Bauer, W.R., Paul, V., Sack, S., Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population. Europace 14 (2012), 230–237.
31. Glotzer, T.V., Hellkamp, A.S., Zimmerman, J., Sweeney, M.O., Yee, R., Marinchak, R., Cook, J., Paraschos, A., Love, J., Radoslovich, G., Lee, K.L., Lamas, G.A., Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. Circulation 107 (2003), 1614–1619.
32. Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
33. Healey J, Connolly S, Alings M, Lopes R. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA). In: ClinicalTrials.gov. Bethesda, (MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01938248. Cited October 21, 2016. Accessed January 3, 2017.
34. Kirchhof P. Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02618577. Cited October 21, 2016. Accessed January 3, 2017.